Literature DB >> 16015629

BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors.

Nikolaus Lubomierski1, Guido Plotz, Marc Wormek, Knut Engels, Susanne Kriener, Jorg Trojan, Bernd Jungling, Stefan Zeuzem, Jochen Raedle.   

Abstract

BACKGROUND: Alterations of BRAF have been implicated in the carcinogenesis of colorectal tumors with microsatellite instability (MSI). These alterations were attributed to defective DNA mismatch repair, which underlies MSI. It was the objective of this study to clarify the role of BRAF in colorectal carcinoma with MSI.
METHODS: After sequencing for BRAF and KRAS in 82 colorectal tumor samples with or without MSI, mismatch repair protein expression was analyzed by immunohistochemistry, and promoter methylation of hMLH1 was analyzed with a methylation-specific polymerase chain reaction. Results were correlated with the germline status of hMLH1 or hMSH2 and clinical characteristics.
RESULTS: BRAF was mutated more often in tumors with MSI than in tumors without MSI (27% vs. 5%; P = 0.016). The most prevalent BRAF alteration, V599E, occurred only in tumors with MSI. BRAF V599E was associated with more frequent hMLH1 promoter methylation (P = 0.07) and loss of hMLH1 (P = 0.02). The median age of patients with BRAF V599E was older compared with the median age of patients without this mutation (P = 0.001; 78 vs. 49 yrs). No BRAF alterations occurred in patients with germline mutations of mismatch repair genes. Five novel BRAF mutations were identified.
CONCLUSIONS: Although BRAF V599E was common in colorectal carcinomas with MSI, it was not a consequence of deficient mismatch repair. The current data showed instead that the BRAF V599E mutation was associated only with a subgroup of colorectal carcinomas with MSI that were obtained from older patients without hereditary nonpolyposis colorectal carcinoma and showed epigenetic silencing of hMLH1. These results indicated that tumors with MSI caused by epigenetic MLH1 silencing have a distinct mutational background from that of tumors with genetic loss of mismatch repair, suggesting that there are two genetically distinct entities of microsatellite-instable tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16015629     DOI: 10.1002/cncr.21266

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.

Authors:  Mireia Gausachs; Pilar Mur; Julieta Corral; Marta Pineda; Sara González; Llúcia Benito; Mireia Menéndez; Josep Alfons Espinàs; Joan Brunet; María Dolores Iniesta; Stephen B Gruber; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

3.  Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Authors:  B Iacopetta; T Watanabe
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 4.  Molecular alterations and biomarkers in colorectal cancer.

Authors:  William M Grady; Colin C Pritchard
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 5.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 6.  DNA mismatch repair and Lynch syndrome.

Authors:  Guido Plotz; Stefan Zeuzem; Jochen Raedle
Journal:  J Mol Histol       Date:  2006-07-04       Impact factor: 2.611

7.  Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner.

Authors:  Takafumi Maeda; Koichi Suzuki; Kazutomo Togashi; Mitsuhiro Nokubi; Masaaki Saito; Shingo Tsujinaka; Hidenori Kamiyama; Fumio Konishi
Journal:  Exp Ther Med       Date:  2011-04-05       Impact factor: 2.447

8.  MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria.

Authors:  Francesca Crucianelli; Rossella Tricarico; Daniela Turchetti; Greta Gorelli; Francesca Gensini; Roberta Sestini; Laura Giunti; Monica Pedroni; Maurizio Ponz de Leon; Serenella Civitelli; Maurizio Genuardi
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

9.  Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects.

Authors:  Hassan Ashktorab; Hassan Brim; Marwa Al-Riyami; Anand Date; Kamla Al-Mawaly; Masoud Kashoub; Rayhaneh Al-Mjeni; Duane T Smoot; Mansoor Al-Moundhri; Suleiman Al-Hashemi; Shyam S Ganguly; Sandy Raeburn
Journal:  Dig Dis Sci       Date:  2008-02-26       Impact factor: 3.199

10.  3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

Authors:  Eliot T McKinley; R Adam Smith; Ping Zhao; Allie Fu; Samir A Saleh; Md Imam Uddin; M Kay Washington; Robert J Coffey; H Charles Manning
Journal:  J Nucl Med       Date:  2013-01-22       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.